Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2017 Dec;44(6):377-380.
doi: 10.1053/j.seminoncol.2018.01.004. Epub 2018 Apr 12.

Proteasome inhibitors: structure and function

Ana T Nunes  1 , Christina M Annunziata  2
Affiliations
Review

Proteasome inhibitors: structure and function

Ana T Nunes et al. Semin Oncol. 2017 Dec.

Abstract

Since 2003, the US Food and Drug Administration approval of bortezomib, a proteasome inhibitor, has changed the management of hematologic malignancies and dramatically improved outcomes for patients with multiple myeloma and mantle cell lymphoma. Since that time, two additional proteasome inhibitors (carfilzomib and ixazomib) have been approved, with other agents and combinations currently under investigation. Proteasomes degrade ubiquitinated proteins or substrates through the ubiquitin-proteasome pathway, a pathway that is utilized in multiple myeloma because of the high protein turnover with immunoglobulin production. Proteasome inhibitors exploit dependence on this pathway, halting protein degradation that ultimately results in apoptosis and cell death. Here we will discuss the structure of the proteasome and the mechanisms of action for proteasome inhibitors to further understand their role in hematologic malignancies.

Keywords: bortezomib; multiple myeloma; proteasome inhibitors; ubiquitin-proteasome pathway.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Chemical Structures of bortezomib, carfilzomib and ixazomib
The circles highlight the active moieties of the individual proteasome inhibitors
Figure 2
Figure 2. Proteasome Structure
The 20S catalytic core binds to the 19S regulatory complex to form the 26S proteasome structure. Proteins that are tagged with ubiquitin bind to the 19S complex and are degraded at the proteolytic β subunits. Bortezomib, carfilzomib and ixazomib all inhibit the β5 subunit thereby inhibiting the catalytic activity of the proteasome.
Figure 3
Figure 3. Mechanism of Proteasome Inhibitors
Proteasome inhibition acts through multiple mechanisms to induce cell death. Inhibition of NF-κB results in downregulation of multiple pro-neoplastic pathways. Activation of the JNK pathway leads to caspase activation and apoptosis. Additionally, interference with the degradation of pro-apoptotic proteins such as Bim, BIK, BID, or Bax and an increase in NOXA activation promotes apoptosis. The depletion of ubiquitin and ER stress with activation of the unfolded protein response can promote apoptosis as well.
See this image and copyright information in PMC

References

    1. King RW, Deshaies RJ, Peters J-M, Kirschner MW. How Proteolysis Drives the Cell Cycle. Science. 1996;274(5293):1652–9. - PubMed
    1. Adams J. The proteasome: structure, function, and role in the cell. Cancer Treatment Reviews. 2003;29(Supplement 1):3–9. - PubMed
    1. Manasanch EE, Orlowski RZ. Proteasome inhibitors in cancer therapy. Nature Reviews Clinical Oncology. 2017;14:417. - PMC - PubMed
    1. Palombella VJ, Rando OJ, Goldberg AL, Maniatis T. The ubiquitin-proteasome pathway is required for processing the NF-kappa B1 precursor protein and the activation of NF-kappa B. Cell. 1994;78(5):773–85. - PubMed
    1. Hideshima T, Chauhan D, Richardson P, Mitsiades C, Mitsiades N, Hayashi T, et al. NF-κB as a Therapeutic Target in Multiple Myeloma. Journal of Biological Chemistry. 2002;277(19):16639–47. - PubMed

MeSH terms